// App-Quantinova.ai

TPS8066 : A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.

Researchers

Presenter

  • Jesus San Miguel

Principal Investigators

  • Marc S. Raab

  • Hartmut Goldschmidt

  • Sagar Lonial

  • Paul G. Richardson

  • Suresh Shelat

  • Eric W. Bleickardt

  • Antonio Palumbo

Medical Centers

  • Clinica Universidad de Navarra, Pamplona, Spain

  • University Clinic Heidelberg, Heidelberg, Germany

  • Emory University, Atlanta, GA

  • Dana-Farber Cancer Institute, Boston, MA

  • Bristol-Myers Sqiubb, Princeton, NJ

  • University of Turin, Turin, Italy

Locations

  • United States

  • Spain

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Multiple Myeloma

Biomarkers

  • N/A

Drug/Treatment

  • Dexamethasone

  • Dekpak 13 Day Taperpak

  • Pomalidomide

  • CC-4047

  • Lenalidomide

  • Elotuzumab

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

Phase

  • II

Study Id's

  • NCT02654132

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved